title: PI3K Inhibitor Improves PFS in BELLE-2 Trial.
abstract: Adding a PI3K inhibitor to anti-estrogen receptor therapy may be a viable treatment option for women with advanced hormone receptor-positive breast cancer that becomes resistant to endocrine therapy, according to findings from the phase III BELLE-2 trial, presented at the 2015 San Antonio Breast Cancer Symposium.
mesh_terms: D000631:Aminopyridines / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017326:Clinical Trials, Phase III as Topic; D003226:Congresses as Topic; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D058539:Phosphatidylinositol 3-Kinase / Q000235:genetics; D000081082:Phosphoinositide-3 Kinase Inhibitors; D016896:Treatment Outcome
chemical_list: D000631:Aminopyridines; D018931:Antineoplastic Agents, Hormonal; D009025:Morpholines; C571178:NVP-BKM120; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000077267:Fulvestrant; D004958:Estradiol; D058539:Phosphatidylinositol 3-Kinase